Oppenheimer Upgrades Chemomab Therapeutics to Outperform, Announces $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones upgrades Chemomab Therapeutics (CMMB) from Perform to Outperform with a $6 price target.

May 06, 2024 | 11:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chemomab Therapeutics was upgraded by Oppenheimer from Perform to Outperform with a new price target of $6.
Upgrades by prominent analysts like those from Oppenheimer can significantly influence investor perception and stock price. The upgrade to Outperform suggests a positive outlook on the stock's future performance, potentially leading to increased investor interest and a rise in stock price. The setting of a $6 price target further indicates a bullish view on the stock's value, which could encourage buying activity.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100